Molecular Biology Reports

, Volume 39, Issue 11, pp 9921–9930 | Cite as

Cytochrome P450 1A1 (CYP1A1) gene polymorphisms and ovarian cancer risk: a meta-analysis

  • Theodoros N. Sergentanis
  • Konstantinos P. Economopoulos
  • Souzana Choussein
  • Nikos F. Vlahos


This meta-analysis aims to examine whether the genotype status of MspI, Ile462Val, and Thr461Asn polymorphisms in Cytochrome P450 1A1 (CYP1A1) is associated with ovarian cancer risk. Eligible case–control studies were identified through search in MEDLINE (end of search: October 2010). Pooled odds ratios (ORs) were appropriately derived from fixed effects or random effects models. Concerning MspI polymorphism, seven studies were eligible (1,051 cases and 1,613 controls); 11 studies were eligible (1,680 cases and 3,345 controls) for Ile462Val and three studies were eligible (349 cases and 785 controls) for Thr461Asn. Ile462Val polymorphism seemed to confer elevated ovarian cancer risk concerning homozygous carriers (pooled OR = 2.65, 95 % CI: 1.40–5.03, p = 0.003, fixed effects), as well as at the recessive model (pooled OR = 2.10, 95 % CI: 1.13–3.92, p = 0.020, fixed effects); these findings were replicated upon Caucasian subjects. MspI polymorphism was not associated with ovarian cancer risk (for heterozygous TC vs TT carriers pooled OR = 1.10, 95 % CI: 0.91–1.34, p = 0.329, fixed effects; for homozygous CC vs. TT carriers pooled OR = 1.11, 95 % CI: 0.65–1.90, p = 0.693, fixed effects). With respect to Thr461Asn polymorphism a finding of borderline statistical significance emerged, pointing to marginally elevated ovarian cancer risk in heterozygous Thr/Asn carriers (pooled OR = 1.62, 95 % CI: 0.97–2.70, p = 0.066, fixed effects), but not in homozygous Asn/Asn carriers (pooled OR = 1.40, 95 % CI: 0.18–10.89, p = 0.749, fixed effects). Ile462Val status seems to represent a meaningful risk factor for ovarian cancer in Caucasians. Additional case–control studies of high methodological quality are needed in order to further substantiate and enrich the present findings. Special attention should be paid upon the design of future studies; Asian and African populations should represent points of focus.


Cytochrome P450 1A1 Ovarian cancer MspI polymorphism Ile462Val polymorphism Thr461Asn polymorphism 



None to report.


  1. 1.
    Androutsopoulos VP, Tsatsakis AM, Spandidos DA (2009) Cytochrome P450 CYP1A1: wider roles in cancer progression and prevention. BMC Cancer 9:187PubMedCrossRefGoogle Scholar
  2. 2.
    Spink DC, Eugster HP, Lincoln DW II, Schuetz JD, Schuetz EG, Johnson JA, Kaminsky LS, Gierthy JF (1992) 17 beta-estradiol hydroxylation catalyzed by human cytochrome P450 1A1: a comparison of the activities induced by 2,3,7,8-tetrachlorodibenzo-p-dioxin in MCF-7 cells with those from heterologous expression of the cDNA. Arch Biochem Biophys 293:342–348PubMedCrossRefGoogle Scholar
  3. 3.
    Crofts F, Taioli E, Trachman J, Cosma GN, Currie D, Toniolo P, Garte SJ (1994) Functional significance of different human CYP1A1 genotypes. Carcinogenesis 15:2961–2963PubMedCrossRefGoogle Scholar
  4. 4.
    Shi X, Zhou S, Wang Z, Zhou Z (2008) CYP1A1 and GSTM1 polymorphisms and lung cancer risk in Chinese populations: a meta-analysis. Lung Cancer 59:155–163PubMedCrossRefGoogle Scholar
  5. 5.
    Zhuo WL, Zhang YS, Wang Y, Zhuo XL, Zhu B, Cai L, Chen ZT (2009) Association studies of CYP1A1 and GSTM1 polymorphisms with esophageal cancer risk: evidence-based meta-analyses. Arch Med Res 40:169–179PubMedCrossRefGoogle Scholar
  6. 6.
    Sergentanis TN, Economopoulos KP (2010) Four polymorphisms in cytochrome P450 1A1 (CYP1A1) gene and breast cancer risk: a meta-analysis. Breast Cancer Res Treat 122:459–469PubMedCrossRefGoogle Scholar
  7. 7.
    Sergentanis TN, Economopoulos KP, Choussein S, Vlahos NF (2011) Cytochrome P450 1A1 gene polymorphisms and endometrial cancer risk: a meta-analysis. Int J Gynecol Cancer 21:323–331PubMedCrossRefGoogle Scholar
  8. 8.
    Economopoulos KP, Choussein S, Vlahos NF, Sergentanis TN (2010) GSTM1, GSTT1 polymorphisms and cervical cancer risk: a meta-analysis. Int J Gynecol Cancer 20:1576–1580PubMedCrossRefGoogle Scholar
  9. 9.
    Cavalli-Sforza LL, Piazza A, Menozzi P, Mountain J (1988) Reconstruction of human evolution: bringing together genetic, archaeological, and linguistic data. Proc Natl Acad Sci USA 85:6002–6006PubMedCrossRefGoogle Scholar
  10. 10.
    Higgins JPT, Green S (2010) Cochrane handbook for systematic reviews of interventions version 5.0.1. The Cochrane Collaboration, 2008. Available from: Accessed 15 June 2010
  11. 11.
    Sergentanis TN, Economopoulos KP (2010) GSTT1 and GSTP1 polymorphisms and breast cancer risk: a meta-analysis. Breast Cancer Res Treat 121:195–202PubMedCrossRefGoogle Scholar
  12. 12.
    Economopoulos KP, Sergentanis TN, Vlahos NF (2010) GSTM1, GSTT1, GSTP1 polymorphisms and ovarian cancer risk: a meta-analysis. Int J Gynecol Cancer 20:732–737PubMedCrossRefGoogle Scholar
  13. 13.
    Sergentanis TN, Economopoulos KP (2011) Cyclin D1 G870A polymorphism and breast cancer risk: a meta-analysis comprising 9,911 cases and 11,171 controls. Mol Biol Rep 38:4955–4963PubMedCrossRefGoogle Scholar
  14. 14.
    Thakkinstian A, McElduff P, D’Este C, Duffy D, Attia J (2005) A method for meta-analysis of molecular association studies. Stat Med 24:1291–1306PubMedCrossRefGoogle Scholar
  15. 15.
    Mikhailova ON, Gulyaeva LF, Prudnikov AV, Gerasimov AV, Krasilnikov SE (2006) Estrogen-metabolizing gene polymorphisms in the assessment of female hormone-dependent cancer risk. Pharmacogenomics J 6:189–193PubMedCrossRefGoogle Scholar
  16. 16.
    Gulyaeva LF, Mikhailova ON, PustyInyak VO, Kim IVt, Gerasimov AV, Krasilnikov SE, Filipenko ML, Pechkovsky EV (2008) Comparative analysis of SNP in estrogen-metabolizing enzymes for ovarian, endometrial, and breast cancers in Novosibirsk, Russia. Adv Exp Med Biol 617:359–366PubMedCrossRefGoogle Scholar
  17. 17.
    Kotsopoulos J, Vitonis AF, Terry KL, De Vivo I, Cramer DW, Hankinson SE, Tworoger SS (2009) Coffee intake, variants in genes involved in caffeine metabolism, and the risk of epithelial ovarian cancer. Cancer Causes Control 20:335–344PubMedCrossRefGoogle Scholar
  18. 18.
    Goodman MT, McDuffie K, Kolonel LN, Terada K, Donlon TA, Wilkens LR, Guo C, Le Marchand L (2001) Case-control study of ovarian cancer and polymorphisms in genes involved in catecholestrogen formation and metabolism. Cancer Epidemiol Biomark Prev 10:209–216Google Scholar
  19. 19.
    Aktas D, Guney I, Alikasifoglu M, Yuce K, Tuncbilek E, Ayhan A (2002) CYP1A1 gene polymorphism and risk of epithelial ovarian neoplasm. Gynecol Oncol 86:124–128PubMedCrossRefGoogle Scholar
  20. 20.
    Sugawara T, Nomura E, Sagawa T, Sakuragi N, Fujimoto S (2003) CYP1A1 polymorphism and risk of gynecological malignancy in Japan. Int J Gynecol Cancer 13:785–790PubMedCrossRefGoogle Scholar
  21. 21.
    Terry KL, Titus-Ernstoff L, Garner EO, Vitonis AF, Cramer DW (2003) Interaction between CYP1A1 polymorphic variants and dietary exposures influencing ovarian cancer risk. Cancer Epidemiol Biomark Prev 12:187–190Google Scholar
  22. 22.
    Sellers TA, Schildkraut JM, Pankratz VS, Vierkant RA, Fredericksen ZS, Olson JE, Cunningham J, Taylor W, Liebow M, McPherson C, Hartmann LC, Pal T, Adjei AA (2005) Estrogen bioactivation, genetic polymorphisms, and ovarian cancer. Cancer Epidemiol Biomark Prev 14:2536–2543CrossRefGoogle Scholar
  23. 23.
    Seremak-Mrozikiewicz A, Drews K, Semczuk A, Jakowicki JA, Mrozikiewicz PM (2005) CYP1A1 alleles in female genital cancers in the Polish population. Eur J Obstet Gynecol Reprod Biol 118:246–250PubMedCrossRefGoogle Scholar
  24. 24.
    Holt SK, Rossing MA, Malone KE, Schwartz SM, Weiss NS, Chen C (2007) Ovarian cancer risk and polymorphisms involved in estrogen catabolism. Cancer Epidemiol Biomarkers Prev 16:481–489PubMedCrossRefGoogle Scholar
  25. 25.
    Delort L, Chalabi N, Satih S, Rabiau N, Kwiatkowski F, Bignon YJ, Bernard-Gallon DJ (2008) Association between genetic polymorphisms and ovarian cancer risk. Anticancer Res 28:3079–3081PubMedGoogle Scholar
  26. 26.
    Heubner M, Wimberger P, Riemann K, Kasimir-Bauer S, Otterbach F, Kimmig R, Siffert W (2010) The CYP1A1 Ile462Val polymorphism and platinum resistance of epithelial ovarian neoplasms. Oncol Res 18:343–347PubMedCrossRefGoogle Scholar
  27. 27.
    Rohlfs RV, Weir BS (2008) Distributions of Hardy-Weinberg equilibrium test statistics. Genetics 180:1609–1616PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2012

Authors and Affiliations

  • Theodoros N. Sergentanis
    • 1
    • 2
  • Konstantinos P. Economopoulos
    • 1
    • 2
  • Souzana Choussein
    • 1
    • 2
  • Nikos F. Vlahos
    • 1
    • 3
  1. 1.School of MedicineUniversity of AthensAthensGreece
  2. 2.Society of Junior DoctorsMaroussi, AthensGreece
  3. 3.Department of Gynecology and Obstetrics, School of MedicineJohns Hopkins UniversityBaltimoreUSA

Personalised recommendations